Immutep Limited — FY2020 Form 20-F
Reporting period: Fiscal year ended June 30, 2020, with comparisons to FY2019. Although the request metadata says “2019 Q4,” this filing is an annual report and does not provide standalone fourth-quarter results. Financial figures below are in Australian dollars (A$) unless noted. The audited statements use IFRS as issued by the IASB and Australian Accounting Standards.
Business context
Immutep is a development-stage biotechnology company focused on LAG-3 immunotherapies for cancer and autoimmune diseases. Its lead candidate, eftilagimod alpha (efti, or IMP321), is being studied in combination with other treatments. The company had no product approved for commercial sale and no material product-sales revenue. Development and manufacturing rely substantially on partners and contractors.
Financial highlights
| Metric | FY2020 | FY2019 |
|---|---|---|
| License revenue | A$7.49 million | A$0.14 million |
| Total revenue and other income | A$16.50 million | A$7.49 million |
| Research, development and intellectual property expense | A$20.40 million | A$16.59 million |
| Corporate administrative expense | A$6.34 million | A$6.37 million |
| Depreciation and amortization | A$2.08 million | A$1.88 million |
| Net loss | A$13.47 million | A$18.34 million |
| Basic and diluted loss per share | A$0.0336 | A$0.0548 |
| Net cash used in operating activities | A$10.84 million | A$15.29 million |
| Cash and cash equivalents at year-end | A$26.32 million | A$16.57 million |
FY2020 total revenue and other income included A$5.97 million of grant income, A$0.28 million of research-material sales, a A$0.35 million foreign-exchange gain, A$2.21 million of warrant fair-value gains and A$0.20 million of interest income. The filing reports no meaningful commercial product margin; the company remained loss-making.
Total assets were A$46.60 million and total liabilities A$13.30 million at June 30, 2020, leaving net assets of A$33.30 million. Current assets were A$31.15 million against current liabilities of A$3.36 million. The convertible-note liability was carried at A$8.79 million; its disclosed contractual cash flows total A$17.88 million, due more than five years out. Lease liabilities were A$0.26 million. No material contingent liabilities or capital commitments were reported.
Financing activities provided A$20.48 million in FY2020, principally through equity issues. The company reported 487.6 million ordinary shares outstanding at year-end. A 10-for-1 share consolidation took effect in November 2019; prior-period per-share data were restated.
Material changes versus FY2019
- Total revenue and other income increased about 120%, chiefly because of a £4 million (reported as A$7.49 million) GSK milestone payment following first-patient dosing in a Phase II ulcerative-colitis trial.
- Net loss narrowed by about 27%, largely reflecting the milestone revenue and higher other income, despite increased R&D spending.
- R&D and intellectual-property expense rose about 23%, primarily because of greater clinical-trial activity, including TACTI-002 and AIPAC.
- Operating cash use declined to A$10.84 million from A$15.29 million. Equity financing increased cash at year-end; cash was A$26.32 million compared with A$16.57 million a year earlier.
Outlook, management commentary and risks
- Management said year-end cash was expected to fund operations for more than 12 months from the filing date, while warning that this forecast was uncertain and that substantial additional funding would be needed to advance development. Directors concluded the company could meet obligations for at least 12 months after the financial statements were issued.
- Management expected AIPAC and TACTI-mel costs to decline as those studies were finalized, while TACTI-002 costs were expected to increase with additional recruitment. R&D spending was also expected to rise as IMP761 advanced.
- For AIPAC, the company reported supportive interim efficacy measures: response rates of 48.3% with efti plus paclitaxel and 38.4% with placebo plus paclitaxel; six-month progression-free proportions of 63% and 54%, respectively. The reported unadjusted progression-free-survival hazard ratio was 0.93. Overall-survival data were expected in the second half of 2020; these interim measures do not establish clinical benefit.
- COVID-19 had not materially affected FY2020 operations or statements, according to management, but could disrupt trial recruitment, sites, suppliers, partner development, milestone timing and access to capital.
- Key risks include recurring losses and operating cash outflows, dependence on future financing and collaboration payments, uncertain clinical and regulatory outcomes, patient recruitment, third-party manufacturing and supply, intellectual-property challenges, competition, foreign-exchange exposure and potential share dilution. The company has no approved products or consistent material revenue source.
- Other notable items: the report identifies A$15.19 million of intangible assets, primarily intellectual property, whose recoverability depends on development prospects. The company had a convertible note with a face value of A$13.75 million and significant outstanding warrants/options. It paid no dividends and did not anticipate paying them in the foreseeable future.
After year-end, 37.1 million unquoted warrants lapsed on August 4, 2020. In August 2020, Immutep also announced an A$671,427 research grant with Monash University. The filing reported no other subsequent event significantly affecting operations or financial position.
Most important facts for investors to verify
- Whether the GSK milestone is a one-time revenue event and what recurring collaboration, royalty or research-material income is realistically expected.
- Clinical-trial updates since filing, especially AIPAC overall-survival results and the interpretation of response and progression-free-survival data for efti combination studies.
- Current cash runway and expected trial spending, including whether later-stage funding will be required and on what terms.
- The convertible note’s repayment, conversion and maturity terms, and the potential dilution from outstanding warrants, options and performance rights.
- Any COVID-19-related trial, supply-chain or partner delays, and any resulting effects on milestones, grants or the carrying value of intellectual property.